Published in Cancer Weekly, April 20th, 2004
Under the terms of the merger agreement, the holders of U.S. Oncology common stock, other than Welsh Carson, will receive $15.05 per share in cash for their shares, which represents an 18.5% premium above the March 19th closing price of $12.70.
The transaction is valued at approximately $1.7 billion, including consideration for outstanding stock options and the assumption of certain debt obligations of U.S. Oncology...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.